Articles tagged with Cancer Cells
Researchers developed a biosensor to measure Mitochondrial Pyruvate Carrier (MPC) activity in malignant cells, finding low MPC activity compared to healthy cells. Treating cancer cells with a new compound restored normal MPC activity, suggesting the carrier's dysfunction is responsible for its inactivity.
Worcester Polytechnic Institute researcher Amity Manning is awarded $747,000 from the National Institutes of Health to explore molecular mechanisms driving genetic instability in cancer cells. The goal is to turn the genetic tables against cancer by understanding how specific molecules affect DNA packaging and organization.
ATF3 is a critical protein that helps repair DNA damage and prevent cancer. When cells experience stress, ATF3 binds to the Tip60 protein, promoting DNA repair and cell response. The study suggests that increasing ATF3 levels could lead to new cancer therapies.
A novel combination of techniques is used to create a biocompatible nanodevice that can deliver localized heating to cancer cells while accurately sensing temperature with diamond nanocrystals. This allows for precise targeting of biological molecules and effective thermal cancer therapy.
Researchers develop novel imaging technology to visualize brain's intricate structures, including neurons and blood vessels. The breakthrough enables scientists to study neurological disorders and understand how brain development shapes individual identity.
A team of international scientists decoded the molecular characteristics of a fatal subtype of leukemia in children, paving the way for new therapeutic approaches. The study identified genetic aberrations and altered gene expression programs that lead to tumorigenesis, providing potential druggable targets.
Researchers discovered that a protein imbalance, specifically between Plcγ1 and Grb2, can lead to cell proliferation and cancer formation. High levels of Grb2 relative to Plcγ1 are associated with a favorable prognosis in ovarian cancer patients.
Researchers at the University of Toronto have discovered a motor protein complex that transports severely damaged DNA within cells. The discovery sheds light on how cancer operates and could lead to new anti-cancer drug targets.
A RIKEN-led team has developed a large-scale map of primary cell-to-cell interactions, revealing common signaling routes between cells and new insights into receptor evolution. This data can contribute to the development of medical treatments by identifying potential targets for therapies in various diseases.
Researchers discovered that cancer cells incorporate chemically modified nucleosides into their DNA, which is toxic to them. The study found that modifying these nucleosides could be used as a specific anti-cancer agent, exploiting epigenetic changes in cancer cells.
A new model suggests that evolutionary pressures from healthy tissue keep cells with cancerous mutations in check. The study proposes that the ecosystem of a healthy tissue landscape allows healthy cells to outcompete those with cancerous mutations, but when this balance changes due to aging or stressors, cancer cells can thrive.
A team of Canadian and British researchers has made a breakthrough discovery about the cell division mechanism, finding that chromosomes emit signals to influence microtubule action. This signaling pathway is crucial for the segregation of chromosomes during cytokinesis, a critical step in cell division.
Researchers have developed a new cancer drug FY26 that is 49 times more potent than Cisplatin, effectively shutting down the metabolism of cancer cells. The drug works by forcing cancer cells to use their mitochondria, which are defective in healthy cells, leading to cell death.
Research from the University of Cambridge found that exhausted immune cells are bad news for infections, but good news for autoimmune diseases like lupus and Crohn's disease. The study suggests that targeting T cell exhaustion could lead to more effective treatments for these conditions.
Scientists at Salk Institute and Sanford Burnham Prebys Medical Discovery Institute have developed a drug that inhibits the first step of autophagy, a process used by cancer cells to recycle nutrients. This breakthrough opens new avenues for treating resistant cancers.
Scientists have developed nanoscale hybrid materials for noninvasive cancer diagnosis, offering improved image resolution and minimal toxicity. These hybrid materials combine strong fluorescence, high photostability, and great biocompatibility, making them promising for clinical bioimaging applications.
RIT professor Hans Schmitthenner is designing molecular imaging compounds that selectively target prostate cancer cells, using contrast dyes for improved detection. The preclinical phase project aims to enhance image-directed biopsies, potentially reducing pain and side effects.
Researchers developed a novel live-imaging system to study gene transcription and nuclear position, enabling simultaneous measurements of these processes. The technique shows high specificity and has potential applications in studying higher-order gene regulation and cell-to-cell heterogeneity.
Researchers found that H. pylori infection causes distinct DNA damage patterns in human cells, resembling those seen in gastric cancer. The study suggests a causal link between the bacterium and cancer development.
Researchers at Helmholtz Zentrum München have found that the viral protein LMP2A helps EBV-infected cells evade immune detection. This may contribute to the development of cancer, particularly in nasopharyngeal carcinoma and Hodgkin's lymphoma.
A new study suggests that cell fusion can initiate cancerous processes and tumor formation through 'genomic catastrophe', leading to chromosomal instability and DNA damage. Fused cells from rat intestinal epithelial cells formed tumors in immunodeficient mice, providing evidence for a molecular mechanism driving neoplastic transformation.
Scientists at Scripps Research Institute found that a natural compound called leinamycin (LNM) E1 can be activated by reactive oxygen species, leading to DNA damage and cell death in cancer cells. The study reveals promising therapeutic potential for LNM E1 against prostate and other cancers.
Researchers at Arizona State University identify five foundations of multicellularity that cancer cells bypass to fulfill their selfish needs, leading to disastrous outcomes for the organism. The study provides clues about how to diagnose and treat cancer, a disease with rapid evolution capabilities.
Researchers discovered that double-strand breaks occur at replication fork stalling sites due to collision. The study found that non-homologous end-joining is the primary repair method used in this context, despite its potential for errors.
Researchers at The Wistar Institute have discovered how a specific variant of the condensin protein complex plays a crucial role in regulating DNA structure and promoting cellular senescence. This finding provides valuable insights into the anti-cancer activity of cells and could lead to the development of new therapies
Researchers at OIST Graduate University mapped the points along the genome where a scaffolding protein called condensin binds. Condensin is essential for reassembling copied genomic fragments into chromosomes and maintaining genetic integrity.
A team of researchers at the IRCM has made a breakthrough discovery about how DNA is organized in our cells. They found that two specific proteins play an essential role in maintaining the proper structure of chromatin.
A recent study found that the thunder god vine extract reduces food intake by up to 80% and causes a 45% decrease in body weight in obese mice. The compound Celastrol enhances leptin action, a hormone signaling fullness to the brain, improving ER function and sensitivity.
Researchers at Winship Cancer Institute of Emory University have discovered a novel strategy to exploit apoptosis in lung cancer treatment by inhibiting the Bcl-2 protein. A new class of compounds has been identified that bind to the BH4 domain of Bcl-2, promoting cancer cell death.
Researchers have designed a nanoparticle-based therapy that effectively treats mice with multiple myeloma, a cancer of immune cells in the bone marrow. The nanoparticles carry a Myc inhibitor, which blocks a protein active in many types of cancer, and increase survival by 23 days compared to control groups.
Researchers from the University of Cambridge captured the process of cytotoxic T cells destroying cancer cells using state-of-the-art imaging techniques. The study reveals the remarkable precision and efficiency with which these cells patrol our bodies, identifying and eliminating virally infected and cancerous cells.
Researchers found that MET inhibitors can have a double-edged effect on tumors, promoting cell-cycle arrest or death in cancer cells while blunting pro-inflammatory reactions in neutrophils. This discovery could lead to optimizing cancer treatment by stratifying patients based on MET expression and dependency.
Scientists at CSHL have developed a method to comprehensively identify binding pockets inside cancer cells that can be targeted by drugs. Using CRISPR, they surveyed about 200 potential targets and identified six known targets and 19 new ones in leukemia cells.
A study published in the Journal of Cell Biology suggests that new understanding of cell division can reveal potential targets for cancer therapy. Researchers have identified key steps in cell division and highlighted novel targets that could be inhibited to block cancer cell division.
Mark Grimes, a UM professor, used new data analysis techniques to study childhood cancer called neuroblastoma. He discovered functional compartmentalization of signaling proteins in cancer cells, which could lead to triggering cell death and improving therapeutic progress.
Research suggests that statin use may delay resistance to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer. Statins block the uptake of dehydroepiandrosterone sulfate, a precursor of testosterone, thereby prolonging time to disease progression.
Researchers at UNC School of Medicine have created a method to find where DNA repair happens throughout the entire human genome. This breakthrough could lead to better and more effective cancer drugs or improvements in existing ones.
Scientists at University of California, San Diego School of Medicine demonstrate ability to reprogram large parts of a cell's signaling network by manipulating key hub in communication networks. This approach shows potential to slow or reverse disease progression, including cancer driven by abnormal cell signaling.
Researchers observe complex biochemical interactions between nerves and cancer cells, challenging conventional wisdom on perineural invasion. This dance-like movement allows cancer cells to invade nerves, leading to poor patient survival and severe complications.
Researchers found that paternally contributed centriole proteins can persist up to ten cell generations, raising the possibility that centrioles may be a non-genetic information carrier. This discovery has profound implications for biology and disease treatment, particularly for understanding centriole-related diseases.
A Purdue University study reveals that cancer drug decitabine combats cell damage by taking the place of nucleotide cytosine, restoring 'meaning' to garbled gene messages. An uptick in 5-hydroxymethylcytosine levels could indicate cancer treatment success.
Researchers discovered that Myc's primary function is to repress well-being genes, making cancer cells vulnerable to cell death. This finding suggests a new approach for cancer therapies, targeting the downregulation of well-being genes to enhance the killer activity of Myc in tumor cells.
University at Buffalo researchers have discovered a way to easily and effectively fasten proteins to nanoparticles, showing promise for developing an HIV vaccine and targeting cancer cells. The new biotechnology uses modified proteins and nanoparticles made of natural pigments and metal, and has been tested with impressive results.
Research reveals FGFR1 amplification in 22.7% of small cell lung cancer tumors, implying applicability to non-small cell lung cancer treatments
Researchers have discovered a protein called LEM that promotes the proliferation of cytotoxic T cells, which kill cancer cells and cells infected with viruses. The discovery could lead to new gene therapies designed to boost infection-fighting cells and provide a robust treatment for patients.
Alessandro Vindigni's research reveals four-way junctions as a critical mechanism for resolving DNA lesions, enabling cells to resume replication and maintain genetic stability. New enzymes, including DNA2, play a key role in this process.
Researchers discovered a previously invisible biological process that may be implicated in the rapid growth of some cancers. The new study reveals that a well-known cancer protein called mTOR can hand off its work to another protein, CDK1, when cells are dividing.
Researchers have developed a method to increase radiation's effectiveness in killing cancer cells by using gold nanoparticles tethered to acid-seeking compounds. The approach, published in PNAS, shows promising results and may improve radiation treatment for cancer patients.
A new study has found a significant link between muscle-building supplements and an increased risk of developing testicular cancer. Men who used these supplements were more than 65% likely to develop the disease compared to those who did not use them.
A recent study published in the JNCI: Journal of the National Cancer Institute found a surprising association between shorter telomeres and decreased cancer mortality. The researchers analyzed data from two prospective cohort studies involving over 64,000 individuals and discovered that those with longer telomeres had higher genetic sc...
Researchers at the University of York have found a potential new treatment for organ-confined prostate cancer using low-temperature plasmas. The study, published in the British Journal of Cancer, suggests LTPs may be a viable alternative to current radiotherapy and photodynamic therapy treatments.
Acute myeloid leukemia (AML) cells exhibit high genetic diversity, driven by convergent evolution and mutation rates, leading to increased treatment resistance. Researchers are exploring a new paradigm that leverages cancer's evolveability to develop more effective treatments.
A new molecule designed to specifically target a cancer-causing transcription factor has shown potential to extend survival in some leukemia patients. The small molecule, AI-10-49, inhibits the progression of acute myeloid leukemia (AML) by sequestering an oncogenic mutant, leaving normal transcription factor activity intact.
Researchers at the University of Missouri-Columbia found that 6-Thioguanine can change how certain cancer cells function, weakening them so they can be killed by other drugs. This discovery could lead to future cancer treatments using combination therapy.
A new MRI technique can detect cancerous cells by identifying telltale sugar molecules shed by the outer membranes of cancerous cells. This method could potentially replace or enhance current imaging tests like mammograms and CT scans, allowing for earlier diagnosis and more effective treatment.
This special issue delves into the latest research on molecular gastronomy, perception of food, growing crops, obesity, and diet's impact on the circadian clock. Researchers discuss the science behind cooking techniques, flavor creation, and how chefs are pioneering new fermentation reactions.
Dr. Sara A. Courtneidge is being recognized by the American Association for Cancer Research (AACR) for her groundbreaking research on Src-family kinases and their role in cancer development. Her work has also focused on promoting women in science, leadership, and mentorship.
Low is being recognized for his pioneering development of low molecular weight ligands to deliver attached therapeutic and imaging agents selectively into pathologic cells such as cancer cells. This targeted therapeutic approach improves potency and reduces toxicity.
Researchers at the University of Virginia have developed a promising drug that targets a specific altered cellular protein driving acute myeloid leukemia. The compound kills cancerous cells while sparing healthy ones, offering a new paradigm for treating leukemia.
Cells sort out hairpin-loop structures meant to encode small RNAs, known as microRNAs, using a specific chemical tag. The discovery has wide-ranging implications for development, health and disease, including cancer.